Top Players - Recombinant Vaccine Industry

Recombinant vaccines are anticipated to gain in popularity due to rising zoonotic disease rates and new technologies for vaccine development. Over the course of the forecast period, the market expansion is anticipated to be driven by an increase in research & development efforts by the major market players to create recombinant vaccines. The high price of vaccinations, low immunogenicity, and the requirement for repeated vaccination are the main reasons that will restrain the growth of the global market for recombinant vaccines.

The market for Recombinant Vaccines is anticipated to reach US$ 1,116.1 million in 2022 and grow at a CAGR of 6.2% over the following five years (2022-2030).

Leading companies in the Recombinant Vaccine Industry:

1. Merk & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.  Merck known as MSD outside the United States and Canada, on June 29’ 2022 announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the generation of innovative technologies for drug discovery and development.

2. Novartis AG

Novartis AG operating through two segments, Innovative Medicines and Sandoz, researches, develops, manufactures, and markets healthcare products worldwide. The company. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. On January 2021, Novartis announced today that it has signed an initial agreement to leverage its manufacturing capacity and capabilities in order to address the COVID-19 pandemic by supporting the production of the Pfizer-BioNTech COVID-19 Vaccine. The agreement will see Novartis utilizing its aseptic manufacturing facilities at its site in Stein, Switzerland.

3. Pfizer Inc.

The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19. Pfizer inc. was founded in 1849 and is headquartered in New York, New York. Pfizer in collaboration with BioNTech on November 2022 Announced their Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine.

4. Sanofi

On November 2022, Sanofi along and GSK’s next generation COVID-19 booster vaccine VIdPrevtyn Beta have been approved by the European Commission and will be readily available for fall-winter COVID-19 vaccination campaigns in Europe. Sanofi operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare in in the United States, Europe, and internationally. Sanofi was founded in 1973 and is headquartered in Paris, France. 

5. GSK plc

GSK plc consumer products are spread across the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. On June 2022, Sanofi-GSK’s vaccine turned to be the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation.

6. GC Biopharma

GC Biopharma (formerly known as Green Cross Corporation) is headquartered in Yongin, South Korea, GC Biopharma is one of the leading plasma protein and vaccine product manufacturers globally and has been dedicated to quality healthcare solutions for more than half a century. Green Cross Corporation was founded in 1967 and is headquartered in Yongin-si, South Korea.

7. Bayer AG

Bayer AG operates through Pharmaceuticals, Consumer Health, and Crop Science segments worldwide. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany. In January 2021 Bayer has signed a collaboration and services agreement with CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA). Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV.

8. Bharat Biotech

World’s first intra-nasal vaccine for COVID developed by Bharat Biotech International Limited (BBIL) got approval on 1 December 2022 from the Central Drugs Standard Control Organisation for emergency use in the age group of 18 and above. In 2022 COVAXIN® developed by Bharat Biotech becomes the 1st COVID-19 vaccine in the world to be rolled out for children.  In November 2021, WHO issued Emergency Use Listing for COVAXIN®. Bharat Biotech started in 1996 is headquartered in Genome Valley, Hyderabad, India. It is a pioneering biotechnology company known for its world R&D and manufacturing capabilities.

9. Serum Institute of India Pvt. Ltd.

On Spetmeber 2022, India’s first indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) ‘CERVAVAC’ was announced, it was an outcome of a partnership between Serum Institute of India (SII), Department of Biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC). Serum Institute of India Pvt. Ltd. is now the world's largest vaccine manufacturer by number of doses produced and sold globally (more than 1.5 billion doses) which includes Polio vaccine, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, Rubella as well as Pneumococcal and Covid-19 vaccines. Serum Institute of India was founded in 1966, headquartered in Pune, Maharashtra, India is is ranked as India's No. 1 biotechnology company.  Serum Institute of India provided COVID vaccines, ChAdOx1 nCoV-1 Coronus virus Vaccine (Recombinant)- COVISHIELD.

10. Johnson & Johnson Services

The company was founded in 1886 and is based in New Brunswick, New Jersey. On February 27, 2021, single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, have been approved by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA), to prevent COVID-19 in individuals 18 years of age and older.

*Definition-

A recombinant vaccination is created using recombinant deoxyribonucleic acid (DNA) technology. This type of vaccination is being used majorly in the COVID-19 treatment protocols.